

Multi Commodity Exchange

BUY

INSTITUTIONAL RESEARCH

| INDUSTRY | | EXCH/ | ANGES | |
|--------------------|---------|---------------|--------|--|
| CMP (as on 13 C | Oct 202 | <i>17)</i> Rs | 1,134 | |
| Target Price | | Rs | 1,342 | |
| Nifty | | | 10,167 | |
| Sensex | | 32,433 | | |
| KEY STOCK DATA | | | | |
| Bloomberg | | MCX IN | | |
| No. of Shares (mn | | 51 | | |
| MCap (Rs bn) / (\$ | | 58/890 | | |
| 6m avg traded val | mn) | 382 | | |
| STOCK PERFORM | ANCE (| %) | | |
| 52 Week high / lo | w | Rs 1,413/930 | | |
| | 3M | 6M | 12M | |
| Absolute (%) | 5.1 | (6.3) | (14.1) | |
| Relative (%) | 3.9 | (16.4) | (31.5) | |
| SHAREHOLDING F | PATTER | N (%) | | |
| Promoters | | | 0 | |
| FIs & Local MFs | | | 33.55 | |
| FPIs | | | 30.64 | |
| Public & Others | | | 35.81 | |
| Source : BSE | | | | |

Amit Chandra

amit.chandra@hdfcsec.com +91-22-6171-7345

Apurva Prasad

apurva.prasad@hdfcsec.com +91-22-6171-7327

Growth tailwinds visible

MCX delivered robust numbers in 2QFY18. Revenue was up 13.6% QoQ to Rs 673mn (our est. was Rs 688mn), led by 17% up-tick in ADTV, and offset by 1.2% fall in realisations. Bullion (29% of ADTV) recovered sharply (+17.5% QoQ), but is still down 40.7% in 1HFY18. Metals (39% of ADTV) recovered sharply (+31.9% QoQ) after GST implementation in **July-17.**

Options trading is going to commence from Oct-17-2017. Initially, only a single 1kg gold option contract will be traded. At first, options trading will be free. Eventually, it will be charged after volumes build up. We believe options will start contributing to the top-line from 1QFY19E. Also, institutional participation (banks, MFs, PMS) in commodities derivatives can be expected to commence in the next six months. If implemented, it will deepen the commodity market and boost ADTV significantly.

MCX has maintained its dominant position with ~90% market share. We see value in MCX based on Financial Summary (Standalone)

Embedded non-linearity, (2) Favourable regulatory environment, and (3) Above normal growth prospects with the start of options trading, institutional participation and launch of indices. We estimate revenue/PAT CAGR of 20/21% over FY17-20E. Maintain BUY with a TP of Rs 1,342, implying a P/E of 35x Sep-19E EPS.

Highlights of the quarter

- MCX and Thomson Reuters launched Thomson Reuters - MCX India Commodity Indices (iCOMDEX, SEBI approval is still pending.
- EBITDA margin stood at 31.3%, up 901bps QoQ (vs our est. of 29.3%), led by top-line growth and nonlinearity benefits.
- Near-term outlook: ADTV is expected to rise in 2H, led by the launch of options and recovery in bullion, metals volumes. Margins will expand gradually, with growth in the top-line. Any regulatory boost will lead to a meaningful upside.

| YE March (Rs mn) | 2QFY18 | 2QFY17 | YoY (%) | 1QFY17 | QoQ (%) | FY16 | FY17 | FY18E | FY19E | FY20E |
|------------------|--------|---------------|---------|--------|------------|-------|-------|-------|-------|-------|
| Net Revenues | 673 | 652 | 3.1 | 592 | 13.6 | 2,349 | 2,594 | 2,864 | 3,559 | 4,440 |
| EBITDA | 211 | 252 | -16.2 | 132 | 59.5 | 767 | 797 | 964 | 1,472 | 2,145 |
| APAT | 283 | 376 | -24.8 | 263 | <i>7.9</i> | 1,085 | 1,263 | 1,279 | 1,688 | 2,230 |
| Diluted EPS (Rs) | 5.6 | 7.4 | -24.8 | 5.1 | <i>7.9</i> | 21.3 | 24.8 | 25.1 | 33.1 | 43.7 |
| P/B (x) | | | | | | 4.8 | 4.3 | 4.1 | 3.9 | 3.6 |
| P/E (x) | | | | | | 53.3 | 45.8 | 45.2 | 34.2 | 25.9 |
| EV / EBITDA (x) | | | | | | 61.1 | 60.7 | 49.6 | 32.1 | 21.7 |
| RoE (%) | | | | | | 9.0 | 9.9 | 9.2 | 11.6 | 14.4 |



Total traded volume increased 17.0% to Rs 14.1tn, while blended realisation dropped 1.2% QoQ to Rs 22/mn

Software services expense is linked to volume growth

Pure transaction revenue was up 15.7% QoQ to Rs 624mn

PAT stood at Rs 283mn, up 7.9% QoQ (lower than our estimate of Rs 313mn) owing to lower other income (Rs 226mn -18.4% QoQ)

Quarterly Financials Snapshot

| Rs mn | 2QFY18 | 2QFY17 | YoY (%) | 1QFY17 | QoQ (%) |
|---------------------------|--------|--------|---------|--------|---------|
| Operating income | 673 | 652 | 3.1 | 592 | 13.6 |
| Software service expenses | 127 | 107 | 18.1 | 114 | 11.2 |
| Employee Expenses | 178 | 144 | 24.2 | 178 | 0.5 |
| Other Operating Expenses | 157 | 150 | 4.6 | 168 | (6.8) |
| EBITDA | 211 | 252 | (16.2) | 132 | 59.5 |
| Interest Cost | 0 | 0 | NM | 0 | NM |
| Depreciation | 48 | 42 | 13.5 | 48 | 0.4 |
| Other Income | 226 | 302 | (25.3) | 277 | (18.4) |
| PBT | 388 | 511 | (24.0) | 361 | 7.6 |
| Tax | 105 | 134 | (21.7) | 98 | 6.8 |
| APAT | 283 | 376 | (24.8) | 263 | 7.9 |
| E/o gains (adj for tax) | 0 | 0 | NM | 0 | NM |
| RPAT | 283 | 376 | (24.8) | 263 | 7.9 |

Source: Company, HDFC Sec Inst Research

Margin Analysis


| MARGIN ANALYSIS | 2QFY18 | 2QFY17 | YoY (bps) | 1QFY17 | QoQ (bps) |
|--|--------|--------|-----------|--------|-----------|
| Software service expenses % of Net Sales | 18.8 | 16.4 | 239 | 19.2 | (42) |
| Employee Expenses % of Net Sales | 26.5 | 22.0 | 450 | 30.0 | (348) |
| Other Operating Expenses % of Net Sales | 23.3 | 23.0 | 34 | 28.4 | (511) |
| EBITDA Margin (%) | 31.3 | 38.6 | (723) | 22.3 | 901 |
| Tax Rate (%) | 27.0 | 26.3 | 77 | 27.2 | (20) |
| APAT Margin (%) | 42.1 | 57.7 | (1,558) | 44.3 | (223) |

The value of India's exchange traded commodity derivatives (ETCD) grew 16.7% QoQ, and was down 14.7% YoY to Rs 15.6tn

Bullions and Metals will drive ADTV growth


MCX has maintained a substantial market share of 90%

India's Exchange Traded Commodity Derivatives (ETCD)




Source: Company, Industry, HDFC sec Inst Research

Market Share Of Key Commodity Exchanges




Source: Company, Industry, HDFC sec Inst Research

Composition Of India's ETCD



Source: Company, Industry, HDFC sec Inst Research

MCX's Traded Value: Sectoral Composition




Source: Company, Industry, HDFC sec Inst Research

MCX's average daily trade value grew after three quarters of decline, and still is ~14% down from the predemonitisation level


Number of traded contracts increased 13.8% QoQ to 55mn

MCX: Quarterly Trading Value Analysis



Source: Company, Industry, HDFC sec Inst Research

MCX: Detailed KPIs Of Contracts Traded



Source: Company, Industry, HDFC sec Inst Research

Valuation

- We expect MCX to post 39% EBITDA CAGR, driven by revenue CAGR of 20% and EBITDA margin expansion (48.1% in FY19E vs 30.7% in FY17) for FY17-20E. Considering the asset-light nature of the business, we expect RoE to expand to 14.3% in FY20E vs 9.9% in FY17
- MCX currently trades at 45.2x FY18E and 34.2x FY19E
 EPS (implying PEG 2.2x ~12% discount to EM average)
- We see significant value in MCX, considering (1) Its strong business franchise, (2) Start of options trading in Oct-17, (3) Embedded non-linearity in business, (4) Favourable regulatory environment and (5) Long-term growth prospects. We maintain a BUY rating with a TP of Rs 1,342, implying a P/E of 35x Sep-FY19 EPS. We downgrade the P/E multiple from 40x earlier to 35x, citing a delay in options launch and risk of increased competition after universal exchange licence comes into force.

MCX: Sensitivity Of Target Price To ADTV Assumptions

| | | PE (x) | | | | | | | |
|-------------------------|-----|--------|-------|-------|-------|-------|--------------|--|--|
| Target price (Rs) | | 25.0 | 30.0 | 35.0 | 40.0 | 45.0 | ADTV in FY12 | | |
| | 226 | 715 | 857 | 1,000 | 1,143 | 1,286 | 44.9% | | |
| | 253 | 751 | 901 | 1,051 | 1,201 | 1,352 | 50.4% | | |
| ADTV Assumption (Rs bn) | 411 | 958 | 1,150 | 1,342 | 1,533 | 1,725 | 81.7% | | |
| | 579 | 1,179 | 1,414 | 1,650 | 1,886 | 2,122 | 115.0% | | |
| | 694 | 1,331 | 1,597 | 1,863 | 2,129 | 2,395 | 138.0% | | |



Change In Estimates

| Particulars | Earlier estimates | Revised estimates | % change |
|-------------------|-------------------|-------------------|----------|
| FY18E | | | |
| Revenue (Rs mn) | 2,878 | 2,864 | (0.5) |
| EBITDA (Rs mn) | 959 | 964 | 0.5 |
| EBITDA margin (%) | 33.3% | 33.7% | 33 |
| EPS (Rs) | 27.2 | 25.1 | (7.8) |
| FY19E | | | |
| Revenue (Rs mn) | 3,444 | 3,559 | 3.3 |
| EBITDA (Rs mn) | 1,351 | 1,472 | 9.0 |
| EBITDA margin (%) | 39.2% | 41.4% | 215 |
| EPS (Rs) | 33.0 | 33.1 | 0.3 |

Source: Company, HDFC sec Inst Research

ADTV And Realisation Assumptions

| Rs bn | FY15 | FY16 | FY17 | FY18E | FY19E | FY20E |
|--------------------------------|------|-------|-------|-------|--------|--------|
| Futures ADTV | 203 | 219 | 226 | 223 | 250 | 263 |
| YoY % | | 7.9% | 2.9% | -1.3% | 12.3% | 5.1% |
| Options ADTV | | | | 31 | 161 | 316 |
| YoY % | | | | | 425.4% | 96.2% |
| Total ADTV | 203 | 219 | 226 | 253 | 411 | 579 |
| YoY % | | 7.9% | 2.9% | 12.2% | 62.3% | 40.8% |
| Realization Of Futures (Rs/mn) | 19.6 | 19.1 | 20.3 | 22.2 | 22.2 | 22.2 |
| YoY % | | -2.8% | 6.5% | 9.4% | -0.3% | 0.0% |
| Realization Of Options (Rs/mn) | | | | 0.0 | 4.4 | 4.4 |
| YoY % | | | | | NM | 0.0% |
| Blended Realization (Rs/mn) | 18.4 | 18.1 | 20.3 | 19.6 | 15.2 | 12.5 |
| YoY % | | -1.6% | 12.0% | -3.8% | -22.1% | -18.0% |



Valuation: Global Exchanges

| | Country | M-Cap | M-Cap Forward P/E (x) | EPS growth | EPS growth | | Forward P/B (x) | | TDA (x) | ROE (%) | | |
|-------------------------------|-------------|-----------|-----------------------|------------|-------------|---------|-----------------|----------|----------|----------|----------|----------|
| | Country | (US\$ mn) | 1-yr fwd | 2-yr fwd | (2-yr CAGR) | PEG (X) | 1-yr fwd | 2-yr fwd | 1-yr fwd | 2-yr fwd | 1-yr fwd | 2-yr fwd |
| Emerging markets | | | | | | | | | | | | |
| MCX (HDFC Sec estimates) | India | 891 | 45.2 | 34.2 | 15.6 | 2.2 | 4.1 | 3.9 | 49.6 | 32.1 | 9.2 | 11.6 |
| Bloomberg Consensus estimates | | | | | | | | | | | | |
| BM&FBovespa SA | Brazil | 15,574 | 22.6 | 19.8 | 14.9 | 1.3 | 2.0 | 2.0 | 15.9 | 14.1 | 8.2 | 9.5 |
| Bursa Malaysia Bhd | Malaysia | 1,268 | 23.2 | 22.4 | 3.7 | 6.1 | 5.9 | 6.3 | 10.5 | 10.2 | 27.2 | 27.9 |
| Bolsa Mexicana | Mexico | 965 | 15.6 | 14.4 | 8.6 | 1.7 | 3.3 | 2.9 | 9.3 | 8.7 | 31.0 | 19.3 |
| Multi Commodity Exchange | India | 891 | 38.0 | 26.8 | 30.5 | 0.9 | 4.2 | 3.5 | 48.9 | 26.6 | 10.5 | 14.0 |
| EM average | | | 24.8 | 20.9 | 14.4 | 2.5 | 3.9 | 3.7 | 21.2 | 14.9 | 19.2 | 17.7 |
| | | | | | | | | | | | | |
| Developed markets | | | | | | | | | | | | |
| CME Group | USA | 46,809 | 25.7 | 24.4 | 66.3 | 0.4 | 2.2 | 2.2 | 16.7 | 17.2 | 8.7 | 8.8 |
| Hong Kong Exchanges | Hong Kong | 34,871 | 34.3 | 30.9 | 12.0 | 2.6 | 7.7 | 7.7 | 17.5 | 15.6 | 23.1 | 24.9 |
| Intercontinental Exchange | USA | 41,142 | 21.1 | 19.5 | 10.0 | 1.9 | 2.6 | 2.5 | 14.3 | 13.3 | 12.1 | 13.1 |
| Deutsche Boerse | Germany | 21,794 | 18.5 | 16.6 | 12.3 | 1.3 | 4.0 | 3.4 | 11.7 | 10.7 | 20.0 | 20.3 |
| Nasdaq OMX | USA | 12,495 | 16.4 | 15.6 | 6.8 | 2.3 | 2.2 | 2.1 | 11.2 | 11.2 | 13.4 | 18.8 |
| Japan Exchange Group | Japan | 10,088 | 26.0 | 25.0 | 2.3 | NM | 4.5 | 4.0 | 15.2 | 14.5 | 15.8 | 15.3 |
| Singapore Exchange | Singapore | 6,026 | 20.8 | 20.7 | 3.5 | 5.9 | 7.9 | 7.0 | 14.1 | 14.2 | 34.3 | 31.7 |
| ASX | Australia | 8,160 | 22.1 | 21.1 | 4.9 | 4.3 | 2.7 | 2.6 | 14.6 | 14.0 | 11.8 | 12.2 |
| CBOE Holdings | USA | 12,408 | 27.6 | 25.3 | 8.3 | 3.0 | 4.4 | 4.0 | 17.3 | 16.0 | 19.3 | 20.2 |
| Hellenic Exchanges | Greece | 348 | 27.2 | 19.0 | 15.0 | 1.3 | 2.3 | 2.4 | 10.8 | 7.8 | 9.3 | 13.1 |
| NZX Ltd | New Zealand | 230 | 18.5 | 16.9 | 10.5 | 1.6 | 4.6 | 4.7 | 10.8 | 10.2 | 24.4 | 26.4 |
| Developed markets average | | | 23.5 | 21.4 | 13.8 | 2.5 | 4.1 | 3.9 | 14.0 | 13.2 | 17.5 | 18.6 |
| Global average | | | 23.8 | 21.2 | 14.0 | 2.5 | 4.0 | 3.8 | 15.9 | 13.6 | 17.9 | 18.4 |

Source: Bloomberg, HDFC sec Inst Research Note: 1-yr refers to FY18/CY17 & 2-yr FY19/CY18

Key risks

- Competition from other exchanges (universal exchange)
- Regulatory delays



INSTITUTIONAL RESEARCH

Income Statement (Standalone)

| YE March (Rs mn) | FY16 | FY17 | FY18E | FY19E | FY20E |
|-----------------------------------|--------|-------|-------|-------------|-------|
| Net Revenues (Rs mn) | 2,349 | 2,594 | 2,864 | 3,559 | 4,440 |
| Growth (%) | 5.6 | 10.4 | 10.4 | 24.2 | 24.8 |
| Software support charges | 374 | 426 | 433 | 499 | 585 |
| Employee Expenses | 406 | 644 | 719 | 791 | 869 |
| SG&A Expenses | 307 | 199 | 203 | 213 | 229 |
| Other Operating Expenses | 497 | 527 | 546 | 583 | 622 |
| EBITDA | 767 | 797 | 964 | 1,472 | 2,134 |
| EBITDA Margin (%) | 32.6 | 30.7 | 33.7 | 41.4 | 48.1 |
| EBITDA Growth (%) | (12.5) | 4.0 | 20.9 | <i>52.7</i> | 44.9 |
| Depreciation | 246 | 186 | 197 | 213 | 233 |
| EBIT | 521 | 612 | 767 | 1,260 | 1,901 |
| Other Income (Including EO Items) | 311 | 1,164 | 1,023 | 1,103 | 1,208 |
| Interest | 0 | 2 | 2 | 2 | 2 |
| PBT | 831 | 1,774 | 1,789 | 2,361 | 3,107 |
| Tax (Incl Deferred) | 413 | 512 | 510 | 673 | 886 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| RPAT | 418 | 1,263 | 1,279 | 1,688 | 2,222 |
| EO (Loss) / Profit (Net Of Tax) | (667) | 0 | 0 | 0 | 0 |
| APAT | 1,085 | 1,263 | 1,279 | 1,688 | 2,222 |
| APAT Growth (%) | (13.2) | 16.4 | 1.3 | 32.0 | 31.6 |
| Adjusted EPS (Rs) | 21.3 | 24.8 | 25.1 | 33.1 | 43.6 |
| EPS Growth (%) | (13.2) | 16.4 | 1.3 | 32.0 | 31.6 |

Source: Company, HDFC sec Inst Research

Balance Sheet (Standalone)

| Dalatice Street (Statistatione) | | | | | |
|------------------------------------|--------|--------|--------|--------|--------|
| YE March (Rs mn) | FY16 | FY17 | FY18E | FY19E | FY20E |
| SOURCES OF FUNDS | | | | | |
| Share Capital - Equity | 510 | 510 | 510 | 510 | 510 |
| Reserves | 11,529 | 13,078 | 13,673 | 14,481 | 15,569 |
| Total Shareholders' Funds | 12,039 | 13,588 | 14,183 | 14,991 | 16,079 |
| Settlement guarantee fund | 1,879 | 1,705 | 1,790 | 1,880 | 1,974 |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Deferred Taxes (Net) | 49 | 75 | 75 | 75 | 75 |
| Long Term Provisions & Others | 234 | 345 | 345 | 345 | 345 |
| TOTAL SOURCES OF FUNDS | 14,201 | 15,713 | 16,393 | 17,291 | 18,473 |
| APPLICATION OF FUNDS | | | | | |
| Net Block | 1,401 | 1,521 | 1,616 | 1,759 | 1,970 |
| Investments | 2,230 | 4,404 | 4,403 | 4,404 | 4,404 |
| LT Loans & Advances | 310 | 393 | 412 | 433 | 454 |
| Total Non-current Assets | 3,941 | 6,318 | 6,432 | 6,596 | 6,829 |
| Debtors | 42 | 28 | 39 | 49 | 61 |
| Other Current Assets | 737 | 943 | 928 | 1,137 | 1,403 |
| Cash & Equivalents | 13,448 | 11,368 | 12,259 | 13,425 | 14,916 |
| Total Current Assets | 14,227 | 12,340 | 13,226 | 14,612 | 16,380 |
| Trading margin from members | 2,473 | 2,000 | 2,273 | 2,875 | 3,642 |
| Other Current Liabilities & Provns | 1,495 | 945 | 991 | 1,042 | 1,094 |
| Total Current Liabilities | 3,967 | 2,945 | 3,265 | 3,916 | 4,735 |
| Net Current Assets | 10,260 | 9,395 | 9,962 | 10,695 | 11,644 |
| TOTAL APPLICATION OF FUNDS | 14,201 | 15,713 | 16,393 | 17,291 | 18,473 |
| | | | | | _ |



Cash Flow (Standalone)


| YE March (Rs mn) | FY16 | FY17 | FY18E | FY19E | FY20E |
|----------------------------|------------|---------------------------------------|---------|---------|---------|
| Reported PBT | 831 | 1,774 | 1,789 | 2,361 | 3,107 |
| Non-operating & EO items | (927) | (1,164) | (1,023) | (1,103) | (1,208) |
| Interest expenses | 0 | 2 | 2 | 2 | 2 |
| Depreciation | 246 | 186 | 197 | 213 | 233 |
| Working Capital Change | 518 | (1,160) | 300 | 412 | 520 |
| Tax Paid | (290) | (512) | (510) | (673) | (886) |
| OPERATING CASH FLOW (a) | 378 | (874) | 754 | 1,211 | 1,768 |
| Capex | (202) | (311) | (286) | (356) | (444) |
| Free cash flow (FCF) | <i>175</i> | (1,185) | 468 | 855 | 1,324 |
| Investments | (2,098) | (2,174) | 0 | 0 | 0 |
| Non-operating Income | 92 | 1,164 | 1,023 | 1,103 | 1,208 |
| INVESTING CASH FLOW (b) | (2,209) | (1,320) | 737 | 748 | 764 |
| Debt Issuance/(Repaid) | 0 | 0 | 0 | 0 | 0 |
| Interest Expenses | (0) | (2) | (2) | (2) | (2) |
| FCFE | <i>175</i> | (1,187) | 466 | 853 | 1,322 |
| Share Capital Issuance | 0 | (0) | 0 | 0 | 0 |
| Dividend | (614) | (895) | (598) | (790) | (1,040) |
| FINANCING CASH FLOW (c) | (614) | (897) | (600) | (792) | (1,042) |
| NET CASH FLOW (a+b+c) | (2,445) | (3,091) | 890 | 1,167 | 1,491 |
| EO Items, Others | 509 | 1,011 | 0 | 0 | 0 |
| Closing Cash & Equivalents | 13,448 | 11,368 | 12,259 | 13,425 | 14,916 |
| | | · · · · · · · · · · · · · · · · · · · | · | · | · |

Source: Company, HDFC sec Inst Research

Key Ratios (Standalone)

| ney natios (standarone) | FY16 | FY17 | FY18E | FY19E | FY20E |
|------------------------------------|-------|-------|-------|-------|-------|
| PROFITABILITY (%) | | | | | |
| GPM | 84.1 | 83.6 | 84.9 | 86.0 | 86.8 |
| EBITDA Margin | 32.6 | 30.7 | 33.7 | 41.4 | 48.1 |
| APAT Margin | 46.2 | 48.7 | 44.6 | 47.4 | 50.0 |
| RoE | 9.0 | 9.9 | 9.2 | 11.6 | 14.3 |
| RoIC (or Core RoCE) | 22.0 | 17.3 | 17.3 | 21.7 | 26.8 |
| RoCE | 6.0 | 6.9 | 6.7 | 8.3 | 10.0 |
| EFFICIENCY | | | | | |
| Tax Rate (%) | 30.8 | 28.8 | 28.5 | 28.5 | 28.5 |
| Fixed Asset Turnover (x) | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 |
| Debtors (days) | 7 | 4 | 5 | 5 | 5 |
| Other Current Assets (days) | 104 | 124 | 110 | 110 | 110 |
| Other Current Liab & Provns (days) | 463 | 299 | 306 | 293 | 278 |
| Cash Conversion Cycle (days) | (353) | (172) | (191) | (178) | (163) |
| Debt/EBITDA (x) | (14) | (12) | (10) | (7) | (5) |
| Net D/E (x) | (1) | (1) | (1) | (1) | (1) |
| Interest Coverage (x) | 3,941 | NM | NM | NM | NM |
| PER SHARE DATA (Rs) | | | | | |
| EPS | 21.3 | 24.8 | 25.1 | 33.1 | 43.6 |
| CEPS | 26.1 | 28.4 | 28.9 | 37.3 | 48.1 |
| Dividend | 6.5 | 15.0 | 10.0 | 13.2 | 17.4 |
| Book Value | 236.1 | 266.4 | 278.1 | 294.0 | 315.3 |
| VALUATION | | | | | |
| P/E (x) | 53.3 | 45.8 | 45.2 | 34.2 | 26.0 |
| P/BV (x) | 4.8 | 4.3 | 4.1 | 3.9 | 3.6 |
| EV/EBITDA (x) | 61.1 | 60.7 | 49.6 | 32.1 | 21.8 |
| OCF/EV (%) | 2.2 | (1.8) | 1.6 | 2.6 | 3.8 |
| FCF/EV (%) | 1.8 | (2.4) | 1.0 | 1.8 | 2.8 |
| FCFE/Mkt Cap (%) | (0.2) | (0.4) | 0.3 | 0.3 | 0.4 |
| Dividend Yield (%) | 0.6 | 1.3 | 0.9 | 1.2 | 1.5 |

RECOMMENDATION HISTORY



| Date | CMP | Reco | Target |
|-----------|-------|------|--------|
| 19-Oct-16 | 1,312 | BUY | 1,667 |
| 27-Oct-16 | 1,299 | BUY | 1,634 |
| 9-Jan-17 | 1,250 | BUY | 1,541 |
| 16-Jan-17 | 1,201 | BUY | 1,503 |
| 11-Apr-17 | 1,238 | BUY | 1,563 |
| 5-May-17 | 1,155 | BUY | 1,558 |
| 11-Jul-17 | 1,098 | BUY | 1,359 |
| 14-Jul-17 | 1,079 | BUY | 1,322 |
| 4-Oct-17 | 1,060 | BUY | 1,371 |
| 14-Oct-17 | 1,134 | BUY | 1,342 |

Rating Definitions

BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period

NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period

SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period



INSTITUTIONAL RESEARCH

Disclosure:

We, Amit Chandra, MBA & Apurva Prasad, MBA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest.

Any holding in stock -No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.





HDFC securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171 7330 www.hdfcsec.com